Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity (Q45418101)

From Wikidata

Jump to navigation Jump to search

scientific article published on 3 April 2006

Language	Label	Description	Also known as
English	Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity	scientific article published on 3 April 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

object named as

vaccinia virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

7

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

4

object named as

Volker Erfle

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

2

object named as

Ingo Drexler

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

author name string

Wolfgang Kastenmuller

1

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Holger Ludwig

3

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Christian Peschel

5

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Helga Bernhard

6

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

language of work or name

0 references

publication date

3 April 2006

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

350

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

276-288

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Dendritic cells and the control of immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Expression of foreign genes in cultured human primary macrophages using recombinant vaccinia virus vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Antigen gene transfer to cultured human dendritic cells using recombinant avipoxvirus vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Cell biology. Cutting and pasting antigenic peptides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Immunization of Patients with Malignant Melanoma with Autologous CD34+ Cell-Derived Dendritic Cells Transduced Ex Vivo with a Recombinant Replication-Deficient Vaccinia Vector Encoding the Human Tyrosinase Gene: A Phase I Trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Modified vaccinia virus Ankara induces moderate activation of human dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Early virus protein synthesis in vaccinia virus-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Phagosomes are competent organelles for antigen cross-presentation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Poxvirus as a vector to transduce human dendritic cells for immunotherapy: abortive infection but reduced APC function

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

DC-virus interplay: a double edged sword

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Gene-based vaccines and immunotherapeutics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Therapeutic dendritic-cell vaccine for chronic HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Role of viral factor E3L in modified vaccinia virus ankara infection of human HeLa Cells: regulation of the virus life cycle and identification of differentially expressed host genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

CD8+ T cell cross-priming via transfer of proteasome substrates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Direct priming and cross-priming contribute differentially to the induction of CD8+ CTL following exposure to vaccinia virus via different routes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Transient host range selection for genetic engineering of modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Nonreplicating vaccinia vector efficiently expresses recombinant genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.02.039

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2006.02.039

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45418101&oldid=2076885991"